Participants
ovarian cancer, shock, breast cancer, organ failure, tumors
OVARIAN CANCER, RECRUITMENT, SHOCK, BREAST CANCER, TUMORS, COMPLICATIONS
Subjects were picked via stratified random sampling, then randomized via a computerized random number generator. The total number of subjects was 42, divided into 21 subjects in the NA-UC-MSCs group and 21 in the placebo (NaCl) group. They hail from three major hospitals across the island of Java: Dr. Hasan Sadikin General Hospital in Bandung, Dr. Moewardi General Hospital in Surakarta, and Dr. Sardjito General Hospital in Yogyakarta. Recruitment was done from 30 January to 24 June 2021.All subjects who participated in this trial had satisfied the inclusion and exclusion criteria. The inclusion criteria were: (1) Subjects 18–75 years old, who had been positively diagnosed with COVID-19 based on real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay of either pharyngeal, sputum, or broncho-alveolar lavage swab specimen; (2) Subjects are classified as severe COVID-19 patients; (3) Not mechanically ventilated upon admission; (4) No other adjunctive treatments were administered; (5) Agreed to participate and signed the informed consent. Meanwhile, the exclusion criteria were: (1) Pregnant, lactating women, or women on a contraceptive program; (2) a history or diagnosis of tumors or a history of breast cancer or ovarian cancer in the mother or sister; (3) SGPT/ALT value five times the upper limit of the normal value; (4) eGFR value < 30 mL/min; (5) requires invasive ventilation; (6) shock; (7) complications of organ failure; (8) had enrolled in other clinical trials within the last 3 months.